masupirdine
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2015 (NCT02580305)
Timeline
Indications
Studied for
Mechanism of action
- Serotonin 6 (5-HT6) receptorANTAGONIST
HTR6 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br- Mol. weight
- 478.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4117187 ↗
Also known as
- suvn-502
- suvn-502
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05397639 | Phase 3 | Nov 1, 2022 | Suven Life Sciences Limited |
| NCT02580305 | Phase 2 | Sep 1, 2015 | Suven Life Sciences Limited |
| NCT03564964 | N/A | — | Suven Life Sciences Limited |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suven Life Sciences Limited | For profit | 3 | 3 | 3 | 2015 |
1 organizations
Page 1 / 1